Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322416 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL491983 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL8553937 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL5839696 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL7230416 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL491616 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL21799504 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL21799790 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| SCHEMBL21799578 | 0.97 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 | |
| Hydrochloric Acid SCHEMBL4364158 | 0.97 | HRH3 (0.67) | HRH3SMN1; SMN2KEAP1MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917015-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | claimed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-119080749-A | Method for preparing hindered amine light stabilizer | 利安隆凯亚(河北)新材料有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-02-15 | — | — | US | disclosed |
| EP-4268851-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING LIPID NANOPARTICLES | EnhancedBio Inc. (KR) | 2023-11-01 | — | — | EP | disclosed |
| US-4161590-A | Fluorinated amphoteric and cationic surfactants | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4079059-A | ANTIMICROBIAL, ALGAE INHIBITORS | MERCK & CO., INC. (US) | 1978-03-14 | — | — | US | disclosed |
| US-4069244-A | THIO-CARBOXYLIC ACIDS | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4033748-A | MICROBIOCIDES | MERCK & CO., INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-3944610-A | N,N-bis-aminoalkylamides of polyoxaperfluoroalkandioic acids, derivatives thereof and process for preparing same | MONTEDISON S.P.A. (IT) | 1976-03-16 | — | — | US | disclosed |
| US-3933829-A | 4-Aminoquinoline derivatives | JOHN WYETH & BROTHER LIMITED (EN) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | FGFR3, FGFR4, FGFR1 | HRH3 938/4885SMN1; SMN2 3141/4885KEAP1 3034/4885 |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | HRH3 3114/4885SMN1; SMN2 3615/4885KEAP1 389/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | HRH3 997/4885SMN1; SMN2 3352/4885KEAP1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.